Commonwealth Equity Services LLC Acquires 253 Shares of Insulet Co. (NASDAQ:PODD)

Commonwealth Equity Services LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODDFree Report) by 1.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,259 shares of the medical instruments supplier’s stock after purchasing an additional 253 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Insulet were worth $2,273,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PODD. Sunbelt Securities Inc. bought a new stake in shares of Insulet in the first quarter valued at about $29,000. Wolff Wiese Magana LLC raised its holdings in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Insulet in the fourth quarter valued at about $34,000. Jones Financial Companies Lllp bought a new stake in shares of Insulet in the fourth quarter valued at about $40,000. Finally, Lindbrook Capital LLC raised its holdings in shares of Insulet by 64.1% in the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PODD. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price objective for the company in a report on Tuesday, May 7th. OTR Global reiterated a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Canaccord Genuity Group boosted their target price on shares of Insulet from $226.00 to $234.00 and gave the stock a “buy” rating in a report on Friday, May 10th. Raymond James reduced their target price on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Finally, Barclays reduced their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating for the company in a report on Monday, May 13th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average price target of $239.18.

View Our Latest Stock Analysis on Insulet

Insulet Trading Up 0.1 %

Insulet stock opened at $196.90 on Friday. The company has a current ratio of 3.74, a quick ratio of 2.75 and a debt-to-equity ratio of 1.72. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $293.64. The stock’s 50 day simple moving average is $186.68 and its two-hundred day simple moving average is $186.26. The firm has a market cap of $13.79 billion, a PE ratio of 59.67, a P/E/G ratio of 3.54 and a beta of 1.16.

Insulet (NASDAQ:PODDGet Free Report) last announced its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business’s quarterly revenue was up 23.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 EPS. Analysts anticipate that Insulet Co. will post 3.11 earnings per share for the current year.

Insider Transactions at Insulet

In other news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, Director Timothy J. Scannell sold 3,300 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark N. Field sold 1,500 shares of the stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total value of $299,940.00. Following the completion of the transaction, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at $2,574,485. The disclosure for this sale can be found here. Insiders sold a total of 13,931 shares of company stock valued at $2,636,286 in the last three months. 0.47% of the stock is currently owned by company insiders.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.